ARRIVE BIO

arrive-bio-logo

Arrive Bio develops therapies that improve healthspan.

#SimilarOrganizations #People #Website #More

ARRIVE BIO

Social Links:

Industry:
Biotechnology Pharmaceutical Therapeutics

Founded:
2019-01-01

Address:
Singapore, Central Region, Singapore

Country:
Singapore

Website Url:
http://www.arrivebio.com

Total Employee:
11+

Status:
Active

Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Tag Manager Google Analytics SSL By Default Global Site Tag HSTS Google Analytics 4


Similar Organizations

artugen-therapeutics-logo

Artugen Therapeutics

Artugen Therapeutics develops biotherapeutic products.

avid-radiopharmaceuticals-logo

Avid Radiopharmaceuticals

Avid Radiopharmaceuticals develops molecular imaging agents for detecting and monitoring chronic human diseases.

chimeron-bio-logo

Chimeron Bio

Chimeron Bio develops agents for personalized cancer gene therapy.

clario-logo

Clario

Clario delivers the endpoint technology solutions for clinical trials.

longevity-biotech-logo

Longevity Biotech

Longevity Biotech develops a new class of therapeutics via artificial protein technology that focuses on pharmaceutical preparation.

saphtx-logo

Saphtx

Saphtx develops protein-based therapeutic strategies for a wide range of diseases.

tivorsan-pharmaceuticals-logo

Tivorsan Pharmaceuticals

Tivorsan Pharmaceuticals is a protein therapeutics company that focuses on treating neuromuscular disorders.

weiben-pharmaceutical-logo

Weiben Pharmaceutical

Weiben Pharmaceutical develops innovative drugs with targets such as c-myc and CaMKIIฮณ.

Current Employees Featured

anuj-gaggar_image

Anuj Gaggar
Anuj Gaggar Co-Founder and CEO @ Arrive Bio
Co-Founder and CEO
2021-04-01

Founder


anuj-gaggar_image

Anuj Gaggar

Official Site Inspections

http://www.arrivebio.com

  • Host name: 151.101.1.195
  • IP address: 151.101.1.195
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Arrive Bio"

Arrive

Arrive is a biotechnology company developing therapies for age-related diseases by applying cutting edge deep learning to complex biologic systems.See details»

Arrive Bio - Crunchbase Company Profile & Funding

Arrive Bio develops therapies that improve healthspan. In Vivo Target Screening System: A system that integrates machine learning, bioinformatics, and a proprietary knowledge โ€ฆSee details»

Arrive Bio - LinkedIn

Arrive Bio Biotechnology Research A biotech company developing therapies that improve healthspan for all people.See details»

ARRIVE BIO, LLC - Dun & Bradstreet

Find company research, competitor information, contact details & financial data for ARRIVE BIO, LLC of San Francisco, CA. Get the latest business insights from Dun & Bradstreet.See details»

Arrive - Products, Competitors, Financials, Employees, โ€ฆ

Arrivebio.com. Overview & Products; People; Founded Year 2019. About Arrive. Arrive is a biotechnology company focused on revolutionizing target discovery for age-related diseases. โ€ฆSee details»

1160 Battery St Ste 100, San Francisco, CA 94111-1233 - OpenGovUS

ARRIVE BIO, LLC is an entity in San Francisco, California registered with the System for Award Management (SAM) of U.S. General Services Administration (GSA). The entity was registered โ€ฆSee details»

Arrive Bio - VentureRadar

Website: https://arrivebio.com/ Provides innovative pharmaceutical discovery for age-related diseases using in vivo screening, machine learning, and bioinformatics to ...See details»

Deep learning platform seeks near-term indications of age-related โ€ฆ

Oct 20, 2021 Silicon Valley and Singapore-based startup Arrive is on a mission to develop therapies for age-related diseases, and has developed a powerful deep learning discovery โ€ฆSee details»

Arrive Bio Overview | SignalHire Company Profile

Get Emails & Phone numbers for Company Arrive Bio's employees View contact details for free by signing up. Get up to 10 free lookups monthly.See details»

Arrive Bio - Drug pipelines, Patents, Clinical trials - Synapse

Explore Arrive Bio with its drug pipeline, therapeutic area, technology platform, 3 news.See details»

ARRIVE BIO LLC San Francisco CA, 94111 - Company Profile - Cortera

Free Business profile for ARRIVE BIO LLC at 1160 Battery St, San Francisco, CA, 94111-1233, US. ARRIVE BIO LLC specializes in: Computer Programming Services.See details»

Connect with us - arrivebio.com

Partnering. Arrive evaluates in-licensing opportunities from discovery through clinical stage assets. Please contact us with non-confidential partnership proposals or inquiries about โ€ฆSee details»

Connect with us - arrivebio.com

Weโ€™d love to hear from you! Get in touch with our team. Contact Us. Your message has been sent!See details»

Arrive Bio - Longevity List

About: Arrive is a biotechnology company developing therapies for age-related diseases by applying cutting edge deep learning to complex biologic systems.See details»

Arrive Bio | LinkedIn

Arrive Bio | 904 followers on LinkedIn. A biotech company developing therapies that improve healthspan for all people. | In Arrive, we are here to develop therapies to improve healthspan โ€ฆSee details»

Arrive Bio profiles - FinalScout

In Arrive, we are here to develop therapies to improve healthspan for all people. Founded in Silicon Valley with a proprietary technology platform that accelerates pharmaceutical drug โ€ฆSee details»

Arrivo BioVentures LLC | VentureRadar

Website: http://arrivobio.com. Develops biologics and small molecules to improve patient lives, with a strong commitment to healthcare innovation and advancements in ...See details»

ARRIVO BIOVENTURES

Arrivo BioVentures is the holding company for Sirtsei Pharmaceuticals, Inc. and Panafina Inc. Arrivo provides management oversite and funding for Sirtsei and Panafina.See details»

Focus on key drivers of ageing. - arrivebio.com

Focus on key drivers of ageing. There are currently over 720 million persons over the age of 65 globally which is expected to double by 2050 to >1.5 billion.¹ Diseases of ageing, including โ€ฆSee details»

ArrivoBio Raises $45M in Series B Financing to Advance Pipeline

โ€œOversubscribed capital fundraising is rare in todayโ€™s market, and todayโ€™s Series B closing is a testament to the strong data behind both pipeline treatments, SP-624 and RABI-767, which haveSee details»

linkstock.net © 2022. All rights reserved